Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer

  • Anshika N. Singh
  • Neeti SharmaEmail author


The Sonic hedgehog signalling is known to play a crucial role in regulating embryonic development, cancer stem cell maintenance and tissue patterning. Dysregulated hedgehog signalling has been reported to affect tumorigenesis and drug response in various human malignancies. Epigenetic therapy relying on DNA methyltransferase and Histone deacetylase inhibitors are being proposed as potential drug candidates considering their efficiency in preventing development of cancer progenitor cells, killing drug resistant cells and also dictating “on/off” switch of tumor suppressor genes and oncogenes. In this docking approach, epigenetic modulators were virtually screened for their efficiency in inhibiting key regulators of SHH pathway viz., sonic hedgehog, Smoothened and Gli using polypharmacological approach. The control drugs and epigenetic modulators were docked with PDB protein structures using AutoDock vina and further checked for their drug-likeness properties. Further molecular dynamics simulation using VMD and NAMD, and MMP/GBSA energy calculation were employed for verifying the stability and entropy of the ligand-receptor complex. EPZ-6438 and GSK 343 (EZH2 inhibitors), CHR 3996 and Mocetinostat (HDAC inhibitors), GSK 126 (HKMT inhibitor) and UNC 1215 (L3MBTL3 antagonist) exhibited multiple-targeted approach in modulating HH signalling. This is the first study to report these epigenetic drugs as potential multi-targeted hedgehog pathway inhibitors. Thus, epigenetic polypharmacology approach can be explored as a better alternative to challenges of acute long term toxicity and drug resistance occurring due to traditional single targeted chemotherapy in the future.


Polypharmacology Epigenetic drugs Hedgehog signalling Cancer therapy 



This work was supported by grants from the Symbiosis Centre for Research and Innovation (SCRI) and Symbiosis School of Biological Sciences (SSBS); Symbiosis International (Deemed University) (SIU), Lavale, Pune, India and Senior Research INSPIRE Fellowship (SRF) from the Department of Science and Technology, Government of India, to Miss Anshika Nikita Singh.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Research Involving Human Participants and/or Animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

10930_2019_9832_MOESM1_ESM.docx (151 kb)
Supplementary material 1 (DOCX 151 kb)


  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30CrossRefGoogle Scholar
  2. 2.
    You J, Jones P (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22:9–20CrossRefGoogle Scholar
  3. 3.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefGoogle Scholar
  4. 4.
    Padma VV (2015) An overview of targeted cancer therapy. Biomedicine 5:19CrossRefGoogle Scholar
  5. 5.
    Tsuruo T, Naito M, Fujita TN, Mashima T, Sakamoto H, Haga N et al (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94:15–21CrossRefGoogle Scholar
  6. 6.
    Lu JJ, Pan W, Hu YJ, Wang YT (2012) Multi-target drugs: the trend of drug research and development. PLoS ONE 7:e40262CrossRefGoogle Scholar
  7. 7.
    Mayank VJ (2015) Molecular docking study of natural alkaloids as multi-targeted hedgehog pathway inhibitors in cancer stem cell therapy. Comput Biol Chem 5:737–742Google Scholar
  8. 8.
    Hanna A, Shevde LA (2016) Hedgehog signaling: modulation of cancer properties and tumor mircroenvironment. Mol Cancer 15:1–14CrossRefGoogle Scholar
  9. 9.
    Briscoe J, Thérond PP (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14:418–431CrossRefGoogle Scholar
  10. 10.
    Markant SL, Esparza LA, Sun J, Barton KL, McCoig LM, Grant GA et al (2013) Targeting sonic hedgehog-associated medullablastoma through inhibition of Aurora and Polo-like kinases. Cancer Res 73:6310–6322CrossRefGoogle Scholar
  11. 11.
    Aberger F, Hutterer E, Sternberg C, Del Burgo PJ, Hartmann TN (2017) Acute myeloid leukemia—strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. Cell Commun Signal 15:1–11CrossRefGoogle Scholar
  12. 12.
    Srinath S, Iyengar A, Mysorekar V (2016) Sonic hedgehog in oral squamous cell carcinoma: an immunohistochemical study. J Oral Maxillofac Pathol 20:377CrossRefGoogle Scholar
  13. 13.
    Gu D, Schlotman KE, Xie J (2016) Deciphering the role of hedgehog signaling in pancreatic cancer. J. Biomed Res 30:353–360Google Scholar
  14. 14.
    Abe Y, Tanaka N (2016) The Hedgehog signaling networks in lung cancer: the mechanisms and roles in tumor progression and implications for cancer therapy. Biomed Res Int. Google Scholar
  15. 15.
    Habib JG, O’Shaughnessy JA (2016) The hedgehog pathway in triple-negative breast cancer. Cancer Med 5:2989–3006CrossRefGoogle Scholar
  16. 16.
    Zeng C, Chen T, Zhang Y, Chen Q (2017) Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24. J Cancer 8:786–792CrossRefGoogle Scholar
  17. 17.
    Gonnissen A, Isebaert S, Haustermans K (2013) Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci 14:13979–14007CrossRefGoogle Scholar
  18. 18.
    Peukert S, Miller-Moslin K (2010) Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. Chem Med Chem 5:500–512CrossRefGoogle Scholar
  19. 19.
    Sheikh A, Alvi AA, Aslam HM, Haseeb A (2012) Hedgehog pathway inhibitors—current status and future prospects. Infect Agents Cancer 7:29CrossRefGoogle Scholar
  20. 20.
    Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers 8:22CrossRefGoogle Scholar
  21. 21.
    Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D (2017) Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opin Investig Drugs 26:133–136CrossRefGoogle Scholar
  22. 22.
    Huang YC, Chao KSC, Liao HF, Chen YJ (2013) Targeting sonic hedgehog signaling by compoundsand derivatives from natural products. Evid Based Complement Altern Med 2013:2013Google Scholar
  23. 23.
    Esteller M (2008) Molecular origins of cancer epigenetics in cancer. N Engl J Med 358:1148–1159CrossRefGoogle Scholar
  24. 24.
    Sharma S, Kelly TK, Jones PA (2009) Epigenetics in cancer. Carcinogenesis 31:27–36CrossRefGoogle Scholar
  25. 25.
    deLera AR, Ganesan A (2016) Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenet 8:1–21CrossRefGoogle Scholar
  26. 26.
    Benedetti R, Conte M, Iside C, Altucci L (2015) Epigenetic-based therapy: from single- to multi-target approaches. Int J Biochem Cell Biol 69:121–131CrossRefGoogle Scholar
  27. 27.
    Csermely P, Ágoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26:178–182CrossRefGoogle Scholar
  28. 28.
    Qi Y, Wang D, Wang D, Jin T, Yang L, Wu H et al (2016) HEDD: the human epigenetic drug database. Database 2016:1–10CrossRefGoogle Scholar
  29. 29.
    Murugan K, Sangeetha S, Ranjitha S, Vimala A, Al-Sohaibani S, Rameshkumar G (2015) HDACiDB: a database for histone deacetylase inhibitors. Drug Des Dev Ther 9:2257–2264CrossRefGoogle Scholar
  30. 30.
    Huang Z, Jiang H, Liu X et al (2012) HEMD: an integrated tool of human epigenetic enzymes and chemical modulators for therapeutics. PLoS ONE 7:1–6CrossRefGoogle Scholar
  31. 31.
    Zeng H, Qiu C, Cui Q (2015) Drug-Path: a database for drug-induced pathways. Database 2015:1–4CrossRefGoogle Scholar
  32. 32.
    Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM et al (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 44:D1036–D1044CrossRefGoogle Scholar
  33. 33.
    Agyeman A, Jha BK, Mazumdar T, Houghton JA (2014) Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget 5:4492CrossRefGoogle Scholar
  34. 34.
    Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16:2743–2748CrossRefGoogle Scholar
  35. 35.
    Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A et al (2016) PubChem substance and compound databases. Nucleic Acids Res 44:D1202–D1213CrossRefGoogle Scholar
  36. 36.
    O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open Babel: an open chemical toolbox. J Cheminform 3:1–14CrossRefGoogle Scholar
  37. 37.
    Thompson MA (2004)Molecular docking using ArgusLab, an efficient shape-based search algorithm and the AScore scoring function. In: ACS Meeting, PhiladelphiaGoogle Scholar
  38. 38.
    Pavletich N, Pabo C (1993) Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers. Science 261:1701–1707CrossRefGoogle Scholar
  39. 39.
    Pepinsky RB, Rayhorn P, Day ES, Dergay A, Williams KP, Galdes A et al (2000) Mapping sonic hedgehog-receptor interactions by steric interference. J Biol Chem 275:10995–11001CrossRefGoogle Scholar
  40. 40.
    Weierstall U, James D, Wang C, White TA, Dingjie W, Wei L et al (2014) Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. Nat Commun 5:3309CrossRefGoogle Scholar
  41. 41.
    Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H et al (2000) The Protein Data Bank. Nucleic Acids Res 28:235–242CrossRefGoogle Scholar
  42. 42.
    Volkamer A, Kuhn D, Rippmann F, Rarey M (2012) Dogsitescorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics 28:2074–2075CrossRefGoogle Scholar
  43. 43.
    Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612CrossRefGoogle Scholar
  44. 44.
    Humphrey W, Dalke A, Schulten K (1996) VMD—visual molecular dynamics. J Mol Graph 14:33–38CrossRefGoogle Scholar
  45. 45.
    Philips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781–1802CrossRefGoogle Scholar
  46. 46.
    Brooks BR, Brooks CL III, Mackerell AD, Nilsson L, Petrella RJ, Roux B et al (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30:1545–1615CrossRefGoogle Scholar
  47. 47.
    Cui F, Yang K, Li Y (2015) Investigate the binding of catechins to trypsin using docking and molecular dynamics simulation. PLoS ONE 10(5):e0125848CrossRefGoogle Scholar
  48. 48.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25CrossRefGoogle Scholar
  49. 49.
    Talevi A (2015) Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol 6:205CrossRefGoogle Scholar
  50. 50.
    Srinivas Reddy AS, Zhang S (2013) Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol 6:41–47CrossRefGoogle Scholar
  51. 51.
    Franci G, Miceli M, Altucci L (2010) Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics 2:731–742CrossRefGoogle Scholar
  52. 52.
    Zhang W, Pei J, Lai L (2017) Computational multitarget drug design. J ChemInf Model 57:403–412CrossRefGoogle Scholar
  53. 53.
    Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:901–906CrossRefGoogle Scholar
  54. 54.
    Kuhn M, von MeringC Campillos M, Jensen LJ, Bork P (2008) STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36:684–688CrossRefGoogle Scholar
  55. 55.
    Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:198–201CrossRefGoogle Scholar
  56. 56.
    Schoffski P, Agulnik M, Stacchiotti S, Davis LE, Villalobos VM, Italiano A (2017) Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950). J Clin Oncol 35:11057CrossRefGoogle Scholar
  57. 57.
    Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M et al (2016) A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol. Google Scholar
  58. 58.
    Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A et al (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 110:7922–7927CrossRefGoogle Scholar
  59. 59.
    Shen JK, Cote GM, Gao Y, Choy E, Mankin HJ, Hornicek FJ et al (2016) Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Sci Rep 6:srep25239CrossRefGoogle Scholar
  60. 60.
    Wen S, Wang J, Liu P, Li Y, Lu W, Hu Y et al (2018) Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo. Cancer Lett 28:35–45CrossRefGoogle Scholar
  61. 61.
    Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tonnissen ERLTM et al (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665–667CrossRefGoogle Scholar
  62. 62.
    Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y et al (2014) Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin Lymphoma. Mol Cancer Ther 13:842–854CrossRefGoogle Scholar
  63. 63.
    deVries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, Blom M et al (2015) Prolonged EZH2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep 10:383–397CrossRefGoogle Scholar
  64. 64.
    Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ et al (2017) EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget 8:13509–13520CrossRefGoogle Scholar
  65. 65.
    IdrisS Lindsay C, Kostiuk M, Andrews C, Cote DW, O’Connell DA et al (2016) Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. J Otolaryngol Head Neck Surg 45:54CrossRefGoogle Scholar
  66. 66.
    Ding M, Zhang H, Li Z, Wang C, Chen J, Shi L et al (2015) The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol 42:458–464CrossRefGoogle Scholar
  67. 67.
    Yu T, Wang Y, Hu Q, Wu W, Wu Y, Wei W et al (2017) The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget 8:98348–98359Google Scholar
  68. 68.
    Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X (2015) EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett 359:275–287CrossRefGoogle Scholar
  69. 69.
    Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH (2016) The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharmacol 77:757–765CrossRefGoogle Scholar
  70. 70.
    Lin W, Chen Y, Zeng L, Ying R, Zhu F (2016) Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells. Zhejiang Da XueBao Yi Xue Ba 45:356–363Google Scholar
  71. 71.
    Swords RT, Perez A, Rodriguez A, Watts JM, Schenk T, Vargas F et al (2015) In acute myeloid leukemia (AML), targeting the histone methyltransferase EZH2 promotes differentiation, impairs clonogenic survival and augments the anti-leukemic effects of the retinoid, all-trans-retinoic acid (ATRA). Blood 126:3786Google Scholar
  72. 72.
    Koppens MAJ, Bounova G, Cornelissen-steijger P (2016) Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition. Oncotarget 1:1–5Google Scholar
  73. 73.
    Sato T, Kaneda A, Tsuji S, Isagawa T, Yamaoto S, Fujita T et al (2013) PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 3:1–9Google Scholar
  74. 74.
    McCabe MT, Ott HM, GanjiG Korenchuk S, Thompson C, Van Aller GS et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112CrossRefGoogle Scholar
  75. 75.
    Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S et al (2011) Phase II study of mocetinostat (MGCD0103) in patients with relapsed and refractory classical Hodgkin lymphoma. Lancet Oncol 12:1221–1228Google Scholar
  76. 76.
    Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S et al (2017) A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol 178:434–441CrossRefGoogle Scholar
  77. 77.
    Fredly H, Gjertsen BT, Bruserud Ø (2013) Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 5:1–13CrossRefGoogle Scholar
  78. 78.
    Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M et al (2010) Discovery of 2-(6-{[6-fluoroquinolin-2-yl)methyl] amino} bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem 53:8663–8678CrossRefGoogle Scholar
  79. 79.
    Smith EM, Zhang L, Walker BA, Davenport EL, Li Aronson, Krige D et al (2015) The combination of HDAC and amino peptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF κB signalling pathway. Oncotarget 6:17314–17327Google Scholar
  80. 80.
    Banerji U, Van Doorn L, Papadatos-PastosD Kristeleit R, Debnam P, Tall M et al (2012) A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 18:2687–2694CrossRefGoogle Scholar
  81. 81.
    Milosevich N, Hof F (2016) Chemical inhibitors of epigenetic methyllysine reader proteins. Biochemistry 55:1570–1583CrossRefGoogle Scholar
  82. 82.
    Xu T, Park S, Giaimo BD, Hall D, Ferrante F, Ho DM et al (2017) RBPJ/CBF1 interacts with L3MBTL3/MBT1 to promote repression of Notch signaling via histone demethylase KDM1A/LSD1. EMBO J 36(21):3232–3249CrossRefGoogle Scholar
  83. 83.
    Ning B, Li W, Zhao W, Wang R (2015) Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) 48:97–109Google Scholar
  84. 84.
    James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL et al (2013) Small-molecule ligandsof methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem 56:7358–7371CrossRefGoogle Scholar
  85. 85.
    Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677CrossRefGoogle Scholar
  86. 86.
    Mottamal M, Zheng S, Huang TL, Wang G (2015) Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20:3898–3941CrossRefGoogle Scholar
  87. 87.
    Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán F, García-Conesa M, Espín J (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 19:6064–6093CrossRefGoogle Scholar
  88. 88.
    Borycka-Kiciak K, Banasiewicz T, Rydzewska G (2017) Butyric acid-a well known molecule revisited. Prz Gastroenterol 12:83–89Google Scholar
  89. 89.
    Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J et al (2017) A phase I trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B- cell lymphomas. Leul Lymphoma 58:2310–2318CrossRefGoogle Scholar
  90. 90.
    Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H et al (2011) Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double blind Phase 2 clinical trials. Nutr Cancer 63:889–898CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Symbiosis School of Biological SciencesSymbiosis International (Deemed University)PuneIndia

Personalised recommendations